Sponsor Overview
Explore verified public information about AVM Biotechnology Inc's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 2 supporting sources.
“AVM Biotechnology is committed to making investigational products available to seriously ill patients who have exhausted other treatment options. Development resources are focused on conducting clinical studies required by regulatory authorities to fully answer important scientific questions about the potential risks and benefits of investigational products, and to obtain regulatory approval.”
“Patients who do not meet the requirements for this clinical trial may be eligible for AVM0703 via AVM Biotechnology’s [Compassionate Use or Expanded Access Program](https://avmbiotech.com/compassionate-use/).”
Active EAPs on ClinicalTrials.gov
Score contribution: 60 — 1 supporting sources.
Conditions: Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Breast Cancer, Prostate Cancer, Gastric Cancer, Ovarian Cancer, Acute Leukemia, Pancreatic Cancer, Spindle Cell Sarcoma, Cancer, Tumor, Solid, Tumor, Brain, Esophageal Andeocarcinoma, Mixed Phenotype AML, Desmoplastic Round Cell Sarcoma
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria The purpose of our compassionate use program is to make AVM0703 available to those patients who have exhausted other treatment options and who do not meet the criteria to enroll in a clinical trial. It is intended to improve access to AVM0703 for patients with serious or immediately life-threatening diseases or conditions who lack other therapeutic options and may benefit from it. Available Therapies via Single-Patient EA AVM0703 Injection is a novel and proprietary formulation of high concentration (24 mg/mL) of dexamethasone. It is the subject of two clinical investigations: • Leukemia and Lymphoma (ClinicalTrials.gov Identifier: NCT04329728) • ARDS (Acute Respiratory Distress Syndrome) mediated by COVD-19 or Influenza (A or B) (ClinicalTrials.gov Identifier: NCT04366115) Disease/Category-Specific EA Policies/Criteria https://avmbiotech.com/wp-content/uploads/2020/09/AVMExternal-EAP.pdf
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.